Recent News Releases

Dec 9, 2019

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high...

Nov 11, 2019

InMed Pharmaceuticals to Present at the Cowen Conference

InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of...

Nov 8, 2019

InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of...

Nov 5, 2019

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a Phase 1 human...

See All News Releases

Latest Presentation

Unlocking the Potential of Cannabinoid Medicines

December 2019

Download pdf

Letter to Shareholders

Annual Letter to Shareholders 2019

January 31, 2019

Download pdf

Company Fact Sheet

Company Fact Sheet

September, 2019

Download pdf

	Fact Sheet (420 KB)

SEDAR^® Filings

Loading data...

Financial Reports

Quarterly and Annual Financial Results

2020

First quarter, 2020 (quarter ended September 30, 2019)

• Quarterly Press Release
• Financial Statements
• MD&A

2019

AGM Documents

• Notice of AGM and Information (Proxy) Circular
• Form of Proxy

Fourth quarter, 2019 (full year ended June 30, 2019)

• Quarterly Press Release
• Financial Statements
• MD&A
• Annual Information Form

Third quarter, 2019 (quarter ended March 31, 2019)

• Quarterly Press Release
• Financial Statements
• MD&A

Second quarter, 2019 (quarter ended December 31, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A

First quarter, 2019 (quarter ended September 30, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A

2018

AGM Documents

• Notice of AGM and Information (Proxy) Circular
• Form of Proxy

Fourth quarter, 2018 (full year ended June 30, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A
• Annual Information Form

Third quarter, 2018 (quarter ended March 31, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A

Second quarter, 2018 (quarter ended December 31, 2017)

• Financial Statements
• MD&A

First quarter, 2018 (quarter ended September 30, 2017)

• Financial Statements
• MD&A

2017

Fourth quarter, 2017 (full year ended June 30, 2017)

• Financial Statements
• MD&A
• Annual Information Form
• Letter from the President and Chief Executive Officer

Third quarter, 2017 (quarter ended March 31, 2017)

• Financial Statements
• MD&A

Second quarter, 2017 (quarter ended December 31, 2016)

• Financial Statements
• MD&A

First quarter, 2017 (quarter ended September 30, 2016)

• Financial Statements
• MD&A

Stock Performance

OTCQX: IMLFFTSX: IN

1d

5d

1m

3m

6m

YTD

1y

5y

10y

-

Loading...

Display Events

 

Dividends

 

Splits

 

Earnings

 

News

Chart Style

Line

Mountain

OHLC

Candlestick

Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings Events data provided by Wall Street Horizon.

OTCQX: IMLFFTSX: IN

Analyst Coverage

Firm	Analyst	E-mail	Phone
Edison Investment Research	Maxim Jacobs	MJacobs@edisongroup.com	+1 (646) 653-7027
ROTH Capital Partners	Jerry Isaacson, Ph.D.	jisaacson@roth.com	+1 (406) 425-0563